Skip to main content

Introducing the Oncology Data Advisor® Fellows Forum: A Valuable Resource for Hematology/Oncology Fellows With Samuel Kareff, MD, MPH

Oncology Data Advisor® · Fellows Forum: A Valuable Resource for Hematology/Oncology Fellows Oncology Data Advisor® is excited to announce the launch of the Fellows Forum, a new resource featuring expert perspectives geared toward Hematology/Oncology Fellows. In this interview, Dr. Samuel Kareff, Chief Hematology/Oncology Fellow at the University of Miami's Sylvester Cancer Center, discusses the educational topics that he is looking forward to sharing his insights on as a Fellows Forum...

Continue reading

Investigating CD19-Targeted CAR T Cells for Autoimmune Diseases: Fabian Mueller, MD

Oncology Data Advisor® · Investigating CD19-Targeted CAR T Cells for Autoimmune Diseases: Fabian Mueller, MD In this interview from the American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Fabian Mueller, the Principal Investigator at the Laboratory of Molecular Immunotherapeutics (LMIT) at the University Hospital of Erlangen, in Germany, about his study which investigated CD19-targeted CAR T cells for refractory systemic autoimmune diseases.   O...

Continue reading

Oncology Data Advisor at the American Society of Hematology (ASH) 2023 Annual Meeting

At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more! Oncology Data Advisor® · Oncology D...

Continue reading

Exploring Educational Opportunities During Hematology/Oncology Fellowship With Matthew Hadfield, DO, and Richa Thakur, MD

In this Oncology Data Advisor Fellows Forum interview, Dr. Matthew Hadfield, Medical Oncology Fellow at Brown University, and Dr. Richa Thakur, Hematology/Oncology Fellow at Northwell Health, explore the different types of educational opportunities available during fellowship, including podcasts and in-person meetings, and strategies for finding the most up-to-date education. Visit i3Health.com to explore the FREE live hematology/oncology meeting series offered by i3 Health, and book one fo...

Continue reading

Investigating Momelotinib for Treatment of Myelofibrosis With Srdan Verstovsek, MD, PhD

Oncology Data Advisor™ · Investigating Momelotinib for Treatment of Myelofibrosis With Srdan Verstovsek, MD, PhD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Srdan Verstovsek, Chief of the Section for Myeloproliferative Neoplasms in the Department of Leukemia at MD Anderson Cancer Center, sat down to discuss his presentation on the results of research regarding momelotinib in treatment of myelofibrosis. This podcast episode was recorded live by Oncology Dat...

Continue reading

Pioneering the Field of Stem Cell Biology With Irving Weissman, MD

At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.  

Continue reading

Pioneering the Field of Stem Cell Biology With Irving Weissman, MD

At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.  

Continue reading

Exploring the Results of Elranatamab for Relapsed/Refractory Multiple Myeloma With Noopur Raje, MD

Oncology Data Advisor™ · Exploring the Results of Elranatamab for Relapsed/Refractory Multiple Myeloma With Noopur Raje, MD Recently, Dr. Noopur Raje, Director of the Center for Multiple Myeloma at Massachusetts General Hospital, sat down with Oncology Data Advisor at the 64th American Society of Hematology (ASH) Annual Meeting to discuss the results of the MagnetisMM-1 study of elranatamab for multiple myeloma that she presented. Dr. Raje elaborates on the efficacy and safety of th...

Continue reading

Introducing the Oncology Data Advisor® Fellows Forum: A Valuable Resource for Hematology/Oncology Fellows With Samuel Kareff, MD, MPH

Oncology Data Advisor® is excited to announce the launch of the Fellows Forum, a new resource featuring expert perspectives geared toward Hematology/Oncology Fellows. In this interview, Dr. Samuel Kareff, Chief Hematology/Oncology Fellow at the University of Miami's Sylvester Cancer Center, shares the educational topics that he is looking forward to sharing his insights on as a Fellows Forum member, including tips for fellowship application, specialty pros and cons, research advances, and collaborations with policymakers and patient advocacy groups.  

Continue reading

Omidubicel-onlv Approved for Reducing Infection and Time to Neutrophil Recovery in Patients With Hematologic Malignancies

The FDA has approved omidubicel-onlv (Omisirge®, Gamida Cell Ltd.) for treatment of adult and pediatric patients 12 and older with hematologic malignancies, to minimize the time to neutrophil recovery and incidence of infection following myeloablative conditioning for umbilical cord transplantation. Approved population: adults and pediatric patients ≥12 with hematologic malignancies Why it matters: "Early-phase studies have demonstrated that ex vivo expansion of umbilical cord blood (UCB) s...

Continue reading

Crizotinib Approved for Treatment of ALK-Positive Inflammatory Myofibroblastic Tumors

The FDA has granted approval to crizotinib (Xalkori®, Pfizer) for treatment of unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)–positive inflammatory myofibroblastic tumors (IMTs) in adult or pediatric patients one year and older. "ALK is a receptor tyrosine kinase (RTK) that is known to be oncogenically activated by point mutations within the tyrosine kinase domain, copy-number amplification, or chromosomal translocations" wrote Jennifer Foster, MD, MPH, Dire...

Continue reading

Learning Needs in Immune Thrombocytopenia

Immune thrombocytopenia (ITP) is a heterogeneous disorder that involves a shortage of platelets, or thrombocytes, and can result in excessive bruising or bleeding. Diagnosis and treatment are challenging due to the lack of specific diagnostic criteria and the widely varying clinical features: some patients remain asymptomatic, whereas others experience troublesome bruising or even life-threatening intracranial hemorrhage. The optimal management of ITP necessitates an individualized approach that...

Continue reading

Hematology/Oncology Fellow Preferences: Continuing Medical Education (CME)

In order to identify the continuing medical education needs and preferences of hematology/oncology fellows, i3 Health administered a survey to participants at several live CME-certified visiting faculty meetings. i3 Health intends to use the results gathered from the survey in the planning and implementation of CME-certified activities. Of the 54 participants who completed surveys, 80% felt that they had adequate time for self-education activities during their fellowship program, compared with 2...

Continue reading

Glasdegib Approved to Treat Acute Myeloid Leukemia

Recently, the FDA approved glasdegib (DaurismoÔ, Pfizer Labs) to be used in combination with low-dose cytarabine (LDAC) for newly diagnosed acute myeloid leukemia (AML) in elderly patients or those ineligible to receive intensive induction chemotherapy. Richard Pazdur, MD, Director of the FDA's Oncology Center of Excellence and Acting Director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, explained, "Intensive chemotherapy is usually used...

Continue reading